Home
/
Tarsus Pharmaceuticals, Inc.
/
Financials
/
Quarterly
Tarsus Pharmaceuticals, Inc. — Quarterly Financials
Quarterly figures from SEC EDGAR XBRL filings (10-Q)
These figures are extracted from XBRL-tagged quarterly reports (10-Q) that Tarsus Pharmaceuticals, Inc. filed with the SEC. Values are as reported for each individual quarter (Q1, Q2, Q3, Q4) — not cumulative year-to-date. Negative figures indicate a loss.
Revenue — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q3
2025
Sep 30, 2025
$118.70M
Nov 4, 2025
Q2
2025
Jun 30, 2025
$102.66M
Aug 6, 2025
Q1
2025
Mar 31, 2025
$78.34M
May 1, 2025
Q3
2025
Sep 30, 2024
$48.12M
Nov 4, 2025
Q2
2025
Jun 30, 2024
$40.81M
Aug 6, 2025
Q1
2025
Mar 31, 2024
$27.61M
May 1, 2025
Q3
2024
Sep 30, 2023
$1.87M
Nov 13, 2024
Q2
2024
Jun 30, 2023
$0
Aug 8, 2024
Q1
2024
Mar 31, 2023
$2.50M
May 8, 2024
Q3
2023
Sep 30, 2022
$0
Nov 9, 2023
Q2
2022
Jun 30, 2022
$15.28M
Aug 11, 2022
Q1
2022
Mar 31, 2022
$539.0K
May 11, 2022
Q3
2022
Sep 30, 2021
$1.24M
Nov 9, 2022
Q2
2022
Jun 30, 2021
$22.02M
Aug 11, 2022
Q1
2022
Mar 31, 2021
$33.43M
May 11, 2022
Q3
2021
Sep 30, 2020
$0
Nov 10, 2021
Q2
2021
Jun 30, 2020
$0
Aug 5, 2021
Q1
2021
Mar 31, 2020
$0
May 11, 2021
Net Income — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q3
2025
Sep 30, 2025
($12.59M)
Nov 4, 2025
Q3
2025
Jun 30, 2025
($20.34M)
Nov 4, 2025
Q2
2025
Jun 30, 2025
($20.34M)
Aug 6, 2025
Q3
2025
Mar 31, 2025
($25.12M)
Nov 4, 2025
Q1
2025
Mar 31, 2025
($25.12M)
May 1, 2025
Q2
2025
Mar 31, 2025
($25.12M)
Aug 6, 2025
Q3
2025
Sep 30, 2024
($23.42M)
Nov 4, 2025
Q2
2025
Jun 30, 2024
($33.29M)
Aug 6, 2025
Q3
2025
Jun 30, 2024
($33.29M)
Nov 4, 2025
Q3
2025
Mar 31, 2024
($35.73M)
Nov 4, 2025
Q2
2025
Mar 31, 2024
($35.73M)
Aug 6, 2025
Q1
2025
Mar 31, 2024
($35.73M)
May 1, 2025
Q3
2024
Sep 30, 2023
($39.15M)
Nov 13, 2024
Q2
2024
Jun 30, 2023
($31.42M)
Aug 8, 2024
Q3
2024
Jun 30, 2023
($31.42M)
Nov 13, 2024
Q1
2024
Mar 31, 2023
($23.42M)
May 8, 2024
Q3
2024
Mar 31, 2023
($23.42M)
Nov 13, 2024
Q2
2024
Mar 31, 2023
($23.42M)
Aug 8, 2024
Q3
2023
Sep 30, 2022
($22.51M)
Nov 9, 2023
Q3
2023
Jun 30, 2022
($5.74M)
Nov 9, 2023
Operating Income — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q3
2025
Sep 30, 2025
($14.53M)
Nov 4, 2025
Q2
2025
Jun 30, 2025
($22.18M)
Aug 6, 2025
Q1
2025
Mar 31, 2025
($26.28M)
May 1, 2025
Q3
2025
Sep 30, 2024
($25.16M)
Nov 4, 2025
Q2
2025
Jun 30, 2024
($33.30M)
Aug 6, 2025
Q1
2025
Mar 31, 2024
($37.68M)
May 1, 2025
Q3
2024
Sep 30, 2023
($40.94M)
Nov 13, 2024
Q2
2024
Jun 30, 2023
($32.82M)
Aug 8, 2024
Q1
2024
Mar 31, 2023
($24.95M)
May 8, 2024
Q3
2023
Sep 30, 2022
($22.91M)
Nov 9, 2023
Q2
2023
Jun 30, 2022
($5.22M)
Aug 10, 2023
Q1
2023
Mar 31, 2022
($19.52M)
May 9, 2023
Q3
2022
Sep 30, 2021
($15.71M)
Nov 9, 2022
Q2
2022
Jun 30, 2021
$7.28M
Aug 11, 2022
Q1
2022
Mar 31, 2021
$10.71M
May 11, 2022
Q3
2021
Sep 30, 2020
($10.14M)
Nov 10, 2021
Q2
2021
Jun 30, 2020
($3.26M)
Aug 5, 2021
Q1
2021
Mar 31, 2020
($2.12M)
May 11, 2021
Q3
2020
Sep 30, 2019
($633.0K)
Nov 25, 2020